Report cover image

Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 195 Pages
SKU # IRE18313224

Description

Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2023-2030


The Biologics Contract Manufacturing Market is projected to reach USD 67.44 billion by 2030 from USD 19.64 billion in 2022, at a CAGR of 16.67% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biologics Contract Manufacturing Market.
  • Based on Product, market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines. The Recombinant Hormones is projected to witness significant market share during forecast period.
  • Based on Platform, market is studied across Mammalian and Microbial. The Mammalian is projected to witness significant market share during forecast period.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders. The Infectious Diseases is projected to witness significant market share during forecast period.
  • Based on Scale of Operation, market is studied across Clinical and Commercial. The Clinical is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Biologics Contract Manufacturing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Biologics Contract Manufacturing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Biologics Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Acino International AG, ADMA Biologics, Inc., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Baxter International, Inc, Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Midas Pharma GmbH, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., Wacker Chemie AG, and WuXi Biologics Co., Ltd..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Biologics Contract Manufacturing Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Biologics Contract Manufacturing Market?
  3. What is the competitive strategic window for identifying opportunities in the Biologics Contract Manufacturing Market?
  4. What are the latest technology trends and regulatory frameworks in the Biologics Contract Manufacturing Market?
  5. What is the market share of the leading vendors in the Biologics Contract Manufacturing Market?
  6. Which modes and strategic moves are suitable for entering the Biologics Contract Manufacturing Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

195 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biologics Contract Manufacturing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for biosimilars and vaccine production
5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
5.1.1.3. Key advantages such as cost and time saving offered by contract services
5.1.2. Restraints
5.1.2.1. Changing trade policies between countries
5.1.3. Opportunities
5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
5.1.4. Challenges
5.1.4.1. Concerns over the breach of intellectual property and patents
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Biologics Contract Manufacturing Market, by Product
6.1. Introduction
6.2. Biosimilar
6.3. Insulin
6.4. Interferons
6.5. Monoclonal Antibodies
6.6. Recombinant Hormones
6.7. Vaccines
7. Biologics Contract Manufacturing Market, by Platform
7.1. Introduction
7.2. Mammalian
7.3. Microbial
8. Biologics Contract Manufacturing Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular Diseases
8.4. Infectious Diseases
8.5. Metabolic Diseases
8.6. Neurology
8.7. Oncology
8.8. Ophthalmology
8.9. Respiratory Disorders
9. Biologics Contract Manufacturing Market, by Scale of Operation
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Americas Biologics Contract Manufacturing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biologics Contract Manufacturing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biologics Contract Manufacturing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie, Inc.
14.1.2. Abzena Ltd.
14.1.3. Acino International AG
14.1.4. ADMA Biologics, Inc.
14.1.5. AGC Biologics
14.1.6. Ajinomoto Bio-Pharma Services
14.1.7. Avid Bioservices, Inc.
14.1.8. Baxter International, Inc
14.1.9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
14.1.10. Cambrex Corporation
14.1.11. Catalent, Inc.
14.1.12. Emergent BioSolutions, Inc.
14.1.13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
14.1.14. JSR Life Sciences, LLC by JSR Group
14.1.15. Kemwell Biopharma Pvt. Ltd.
14.1.16. Lonza Group Ltd.
14.1.17. Midas Pharma GmbH
14.1.18. ProBioGen AG
14.1.19. Recipharm AB
14.1.20. Rentschler Biopharma SE
14.1.21. Samsung Biologics
14.1.22. Thermo Fisher Scientific, Inc.
14.1.23. Toyobo Co. Ltd.
14.1.24. Wacker Chemie AG
14.1.25. WuXi Biologics Co., Ltd.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us